+36 % change
Extra-EU imports of CN 30024190 were up 36% in 2025 compared with 2022 (€2.71 billion), calculated from Eurostat values.
Eurostat14.36 EUR billion
EU exports of CN 30024190 to countries outside the EU were worth €14.36 billion in 2025.
Eurostat12.08 EUR billion
Trade between EU member states in CN 30024190 (intra-EU arrivals) came to €12.08 billion in 2025.
EurostatSource: Eurostat
Why this market is moving now
- Extra-EU import value moved +36% from 2022 to 2025, a direct read on EU demand for sourced supply.
- Supply is concentrated: one country provided a large share of extra-EU imports in 2025.
- US employment in the core industry shifted +23% since 2020.
- Clinical research is active, with studies recruiting now.
What this market covers
Vaccines that protect people against anthrax, given to military staff, lab workers and for stockpiles. Government agencies are the main buyers.
Typical segments
- Adsorbed vaccines
- Recombinant vaccines
- Post exposure use
- Military use
- Veterinary vaccines
Who buys
- Government agencies
- Military health services
- Laboratories
Largest non-EU suppliers to the EU
| Country | Import value |
|---|---|
| United States from 1995 -> 2000) | 3,087.6 EUR million |
| United Kingdom | 184.5 EUR million |
| Canada | 179.2 EUR million |
| Singapore | 134.9 EUR million |
| Switzerland | 41.5 EUR million |
| Australia | 17.0 EUR million |
Key figures
Each figure links to the page it came from.
| Figure | Value | Year | Source |
|---|---|---|---|
| The EU imported €3.68 billion of products under CN code 30024190 (Vaccines for human medicine) from outside the EU in 2025. | 3.68 EUR billion | 2025 | Eurostat |
| Extra-EU imports of CN 30024190 were up 36% in 2025 compared with 2022 (€2.71 billion), calculated from Eurostat values. | +36 % change | 2025 | Eurostat |
| EU exports of CN 30024190 to countries outside the EU were worth €14.36 billion in 2025. | 14.36 EUR billion | 2025 | Eurostat |
| Trade between EU member states in CN 30024190 (intra-EU arrivals) came to €12.08 billion in 2025. | 12.08 EUR billion | 2025 | Eurostat |
| United States from 1995 -> 2000) was the largest non-EU supplier of CN 30024190 to the EU in 2025, with €3.09 billion, or 84% of extra-EU imports. | 3.09 EUR billion | 2025 | Eurostat |
| EU exports of CN 30024190 to the United States were €6.94 billion in 2025. | 6.94 EUR billion | 2025 | Eurostat |
| The average value of extra-EU imports of CN 30024190 was €2,053.74 per kilogram in 2025, calculated from Eurostat value and weight. | 2,053.74 EUR per kg | 2025 | Eurostat |
| Belgium was the largest EU exporter of CN 30024190 to non-EU countries in 2025, at €8.74 billion. | 8.74 EUR billion | 2025 | Eurostat |
| The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023. | 3,116 enterprises | 2023 | Eurostat |
| EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023. | 428.65 EUR billion | 2023 | Eurostat |
| NACE class C2120 employed 600,730 people across the EU in 2023. | 600,730 persons employed | 2023 | Eurostat |
| The US had 830 private establishments in NAICS 325414 (Biological product (except diagnostic) manufacturing) in 2025. | 830 establishments | 2025 | U.S. Bureau of Labor Statistics |
| NAICS 325414 employed an average of 46,853 people in US private industry in 2025. | 46,853 jobs | 2025 | U.S. Bureau of Labor Statistics |
| US employment in NAICS 325414 changed by +23% between 2020 (38,064 jobs) and 2025, calculated from BLS figures. | +23 % change | 2025 | U.S. Bureau of Labor Statistics |
| Average annual pay in US NAICS 325414 was $124,162 in 2025. | 124,162 USD per year | 2025 | U.S. Bureau of Labor Statistics |
| ClinicalTrials.gov lists 81 registered studies for the condition "anthrax". | 81 registered studies | 2026 | U.S. National Library of Medicine (ClinicalTrials.gov) |
| 3 of those studies were recruiting participants when checked in November 2026. | 3 recruiting studies | 2026 | U.S. National Library of Medicine (ClinicalTrials.gov) |
| PubMed indexed 11 papers mentioning "anthrax vaccine" in the title or abstract in 2025. | 11 papers | 2025 | U.S. National Library of Medicine (PubMed) |
What the full report covers
- 1
Executive summary
The answer on two pages: size, growth and what drives it.
- 2
Market size and outlook
History, the current year and a five-year view with base, low and high cases.
- 3
Segments and regions
Splits by product, buyer and geography across the US, Europe and MEA.
- 4
Company profiles
The main players, how they compete and where they are investing.
- 5
Data and method
Every figure in Excel, with the sources and assumptions behind it.
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the European Union market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the EU anthrax vaccine market?
There is no single official market total. Eurostat trade data shows the EU imported €3.68 billion of goods under CN 30024190 from outside the EU in 2025 and exported €14.36 billion.
Where does the EU import anthrax vaccine from?
United States from 1995 -> 2000) was the largest non-EU supplier in 2025. The next largest were United Kingdom, Canada, Singapore.
What is the average import price of anthrax vaccine in the EU?
Dividing Eurostat import value by weight gives about €2,053.74 per kilogram for CN 30024190 in 2025.
Which EU countries export the most anthrax vaccine?
Belgium led EU exports to non-EU countries in 2025, followed by Italy, France.
How many clinical trials study anthrax?
ClinicalTrials.gov lists 81 registered studies.
How many US companies are in the anthrax vaccine industry?
BLS counts 830 private establishments in NAICS 325414 (Biological product (except diagnostic) manufacturing), the closest official industry.
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, partner EXT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 3679068432
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, flow import, 2022 VALUE_IN_EUROS 2705293916; 2025 VALUE_IN_EUROS 3679068432
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 14363544122
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, partner INT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 12077708241
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, partner US, flow import, 2025, VALUE_IN_EUROS 3087593503
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, partner US, flow export, 2025, VALUE_IN_EUROS 6941553797
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30024190, flow import, 2025, VALUE_IN_EUROS 3679068432, QUANTITY_IN_100KG 17914
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter BE, product 30024190, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 8743086346
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs ENT_NR, 2023, 3116
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs NETTUR_MEUR, 2023, 428651
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs EMP_NR, 2023, 600730
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325414, annual_avg_estabs 830
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325414, annual_avg_emplvl 46853
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2020 annual_avg_emplvl 38064; 2025 annual_avg_emplvl 46853
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325414, avg_annual_pay 124162
- U.S. National Library of Medicine (ClinicalTrials.gov): ClinicalTrials.gov API v2, condition "anthrax" (2026-11-04)
query.cond=anthrax totalCount 81
- U.S. National Library of Medicine (ClinicalTrials.gov): ClinicalTrials.gov API v2, condition "anthrax", status recruiting (2026-11-04)
filter.overallStatus=RECRUITING totalCount 3
- U.S. National Library of Medicine (PubMed): PubMed search "anthrax vaccine"[tiab] AND 2025[dp] (2026-11-04)
esearch count 11
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline